Display options
Cite
De Mattia E, Roncato R, Palazzari E, et al. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol. 2020;11:897doi: 10.3389/fphar.2020.00897.
De Mattia, E., Roncato, R., Palazzari, E., Toffoli, G., & Cecchin, E. (2020). Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Frontiers in pharmacology, 11897. https://doi.org/10.3389/fphar.2020.00897
De Mattia, Elena, et al. "Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy." Frontiers in pharmacology vol. 11 (2020): 897. doi: https://doi.org/10.3389/fphar.2020.00897
De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol. 2020 Jun 17;11:897. doi: 10.3389/fphar.2020.00897. eCollection 2020. PMID: 32625092; PMCID: PMC7311751.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2020 Jun 17;11:897. doi: 10.3389/fphar.2020.00897. eCollection 2020.

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.

Frontiers in pharmacology

Elena De Mattia, Rossana Roncato, Elisa Palazzari, Giuseppe Toffoli, Erika Cecchin

Affiliations

  1. Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  2. Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.

PMID: 32625092 PMCID: PMC7311751 DOI: 10.3389/fphar.2020.00897

Abstract

Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the standard of care for patients with Locally Advanced Rectal Cancer (LARC). Current selection for nCRT is based on clinical criteria regardless of any molecular marker. Pharmacogenomics may be a useful strategy to personalize and optimize nCRT in LARC. This review aims to summarize the most recent and relevant findings about the role of germline and somatic pharmacogenomics in the prediction of nCRT outcome in patients with LARC, discussing the state of the art of their application in the clinical practice. A systematic literature search of the PubMed database was completed to identify relevant English-language papers published up to January 2020. The chemotherapeutic backbone of nCRT is represented by fluoropyrimidines, mainly metabolized by DPD (Dihydro-Pyrimidine Dehydrogenase,

Copyright © 2020 De Mattia, Roncato, Palazzari, Toffoli and Cecchin.

Keywords: germline; mutation; neo-adjuvant chemoradiotherapy; pharmacogenomics; polymorphism; rectal cancer; somatic

References

  1. Ann Surg Oncol. 2014 Aug;21(8):2642-9 - PubMed
  2. J Clin Oncol. 1994 Nov;12(11):2248-53 - PubMed
  3. Eur J Cancer. 2018 Nov;104:210-218 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):924-930 - PubMed
  5. Tumour Biol. 2010 Jan;31(1):23-32 - PubMed
  6. Am J Hum Genet. 2019 Jun 6;104(6):1158-1168 - PubMed
  7. BMC Cancer. 2004 Mar 25;4:11 - PubMed
  8. Front Pharmacol. 2018 Oct 04;9:1101 - PubMed
  9. Clin Pharmacol Ther. 2017 Mar;101(3):341-358 - PubMed
  10. Hum Genet. 1999 Jan;104(1):1-9 - PubMed
  11. Drug Resist Updat. 2015 May;20:39-70 - PubMed
  12. Clin Cancer Res. 2020 Jan 1;26(1):183-192 - PubMed
  13. Genet Med. 2017 Feb;19(2):215-223 - PubMed
  14. Ann Surg Oncol. 2013 Jul;20(7):2166-71 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):149-57 - PubMed
  16. Oncol Lett. 2012 Nov;4(5):1056-1060 - PubMed
  17. JAMA Oncol. 2016 May 1;2(5):655-662 - PubMed
  18. PLoS One. 2015 Dec 03;10(12):e0144000 - PubMed
  19. Radiother Oncol. 2010 Jan;94(1):76-81 - PubMed
  20. Front Pharmacol. 2018 Apr 13;9:367 - PubMed
  21. Oncotarget. 2016 Jun 7;7(23):34149-57 - PubMed
  22. Hum Mol Genet. 2004 Jan 1;13(1):35-45 - PubMed
  23. Int J Mol Sci. 2019 Nov 05;20(21): - PubMed
  24. Radiother Oncol. 2020 May 5;149:30-37 - PubMed
  25. Pharmacogenomics. 2015;16(11):1277-86 - PubMed
  26. Eur J Hum Genet. 2020 Apr;28(4):508-517 - PubMed
  27. Int J Surg Oncol. 2012;2012:406830 - PubMed
  28. J Clin Oncol. 2016 Jan 20;34(3):227-34 - PubMed
  29. Pharmacogenomics J. 2016 Jun;16(3):249-65 - PubMed
  30. Int J Cancer. 2020 Jan 1;146(1):94-102 - PubMed
  31. Clin Cancer Res. 2011 May 15;17(10):3455-68 - PubMed
  32. Int J Cancer. 2015 Dec 15;137(12):2971-80 - PubMed
  33. Radiat Oncol. 2015 Dec 01;10:247 - PubMed
  34. Hum Genomics. 2018 May 25;12(1):26 - PubMed
  35. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):138-44 - PubMed
  36. Virchows Arch. 2019 Jul;475(1):39-47 - PubMed
  37. Int J Mol Sci. 2016 Jan 14;17(1): - PubMed
  38. Pharmacogenet Genomics. 2006 Nov;16(11):817-24 - PubMed
  39. Surg Oncol. 2013 Jun;22(2):105-11 - PubMed
  40. Int J Mol Sci. 2017 Jun 27;18(7): - PubMed
  41. Drug Resist Updat. 2018 Jul;39:18-40 - PubMed
  42. Pharmacogenomics. 2006 Jan;7(1):67-88 - PubMed
  43. Pharmacogenomics J. 2011 Jun;11(3):214-26 - PubMed
  44. Pharmacogenomics J. 2017 Jun;17(3):265-273 - PubMed
  45. Eur J Cancer. 2016 Feb;54:40-48 - PubMed
  46. Gut. 2019 Apr;68(4):663-671 - PubMed
  47. Pathol Res Pract. 2016 Jul;212(7):598-603 - PubMed
  48. Ann Surg. 2011 Sep;254(3):486-92; discussion 492-3 - PubMed
  49. Front Oncol. 2019 Nov 26;9:1312 - PubMed
  50. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):669-76 - PubMed
  51. Turk J Gastroenterol. 2019 Jan;30(1):3-14 - PubMed
  52. Pharmacogenomics. 2012 Nov;13(14):1635-50 - PubMed
  53. Oncol Lett. 2019 Jan;17(1):1062-1070 - PubMed
  54. Int J Hematol. 2013 Jan;97(1):37-42 - PubMed
  55. J Clin Oncol. 2011 Mar 1;29(7):875-83 - PubMed
  56. Onco Targets Ther. 2015 Aug 27;8:2291-301 - PubMed
  57. Radiother Oncol. 2014 Oct;113(1):1-9 - PubMed
  58. Int J Clin Pharmacol Ther. 2007 Aug;45(8):423-30 - PubMed
  59. Oncotarget. 2016 Apr 12;7(15):19781-93 - PubMed
  60. Int J Oncol. 2000 Mar;16(3):555-60 - PubMed
  61. Cancer Res. 1995 Apr 1;55(7):1407-12 - PubMed
  62. Radiat Oncol J. 2018 Sep;36(3):218-226 - PubMed
  63. Sci Rep. 2019 Sep 10;9(1):13008 - PubMed
  64. Front Pharmacol. 2017 Oct 10;8:712 - PubMed
  65. Pharmacogenomics J. 2011 Dec;11(6):437-43 - PubMed
  66. Eur J Cancer. 2009 May;45(8):1333-51 - PubMed
  67. Carcinogenesis. 2007 Mar;28(3):657-64 - PubMed
  68. Am J Cancer Res. 2015 Sep 15;5(10):3231-40 - PubMed
  69. J Cancer. 2018 Feb 28;9(6):1067-1077 - PubMed
  70. Cancer Treat Rev. 2019 Sep;79:101893 - PubMed
  71. Front Biosci (Schol Ed). 2014 Jan 01;6:110-9 - PubMed
  72. Radiother Oncol. 2009 Aug;92(2):215-20 - PubMed
  73. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):600-5 - PubMed
  74. Med Oncol. 2018 Sep 11;35(11):145 - PubMed
  75. Dis Colon Rectum. 2007 Sep;50(9):1363-9 - PubMed
  76. Med Sci Monit. 2015 Oct 12;21:3068-76 - PubMed
  77. Radiother Oncol. 1998 May;47(2):113-23 - PubMed
  78. Dis Colon Rectum. 2016 Dec;59(12):1200-1208 - PubMed
  79. Clin Cancer Res. 2019 May 15;25(10):3046-3053 - PubMed
  80. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263 - PubMed
  81. Lancet. 2018 Jun 23;391(10139):2537-2545 - PubMed
  82. Clin Cancer Res. 2019 Sep 15;25(18):5561-5571 - PubMed
  83. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):765-774 - PubMed
  84. Int J Mol Sci. 2016 Sep 05;17(9): - PubMed
  85. Pharmacogenomics J. 2015 Feb;15(1):77-83 - PubMed
  86. Front Oncol. 2015 Dec 22;5:286 - PubMed
  87. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1090-8 - PubMed
  88. Int J Cancer. 2019 Dec 1;145(11):3163-3172 - PubMed
  89. Curr Pharm Biotechnol. 2017;18(3):204-209 - PubMed
  90. J Clin Oncol. 2001 Mar 15;19(6):1779-86 - PubMed
  91. J Natl Cancer Inst. 2014 Nov 07;106(12): - PubMed
  92. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1319-27 - PubMed
  93. Front Pharmacol. 2020 Feb 07;11:36 - PubMed
  94. Hum Mol Genet. 2014 Apr 15;23(8):1957-63 - PubMed
  95. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):595-602 - PubMed
  96. Clin Pharmacol Ther. 2019 Apr;105(4):994-1002 - PubMed
  97. J Clin Oncol. 2014 Apr 1;32(10):1031-9 - PubMed
  98. Clin Chem Lab Med. 2010 Apr;48(4):447-59 - PubMed
  99. Ann Surg Oncol. 2016 Aug;23(8):2548-55 - PubMed
  100. Cancer Lett. 2008 Dec 18;272(2):221-5 - PubMed
  101. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):500-4 - PubMed
  102. Br J Cancer. 2017 Oct 24;117(9):1269-1277 - PubMed
  103. Lancet Oncol. 2015 Dec;16(16):1639-50 - PubMed
  104. Ann Oncol. 2015 Sep;26(9):1936-1941 - PubMed
  105. J Cancer Res Clin Oncol. 2010 Nov;136(11):1681-9 - PubMed
  106. Br J Cancer. 2011 Nov 22;105(11):1654-62 - PubMed
  107. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):350-7 - PubMed
  108. Lancet Oncol. 2018 Nov;19(11):1459-1467 - PubMed
  109. Recent Results Cancer Res. 2014;203:189-201 - PubMed
  110. Pharmacogenomics. 2010 Jun;11(6):747-61 - PubMed
  111. Asian Pac J Cancer Prev. 2015;16(2):713-8 - PubMed
  112. Medicine (Baltimore). 2015 Nov;94(45):e1955 - PubMed
  113. Colorectal Dis. 2013 Apr;15(4):428-35 - PubMed
  114. Radiother Oncol. 2019 May;134:110-118 - PubMed
  115. Cancer. 2013 Mar 1;119(5):1106-12 - PubMed
  116. Annu Rev Genomics Hum Genet. 2007;8:37-55 - PubMed
  117. Am J Clin Oncol. 2017 Dec;40(6):535-542 - PubMed
  118. Clin Pharmacol Ther. 2018 Feb;103(2):210-216 - PubMed
  119. Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):24-39 - PubMed
  120. Int J Biol Markers. 2003 Jul-Sep;18(3):218-21 - PubMed
  121. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1094-101 - PubMed
  122. Eur J Cancer. 2019 Jan;107:60-67 - PubMed
  123. Front Immunol. 2016 Feb 22;7:61 - PubMed
  124. Hum Genomics. 2019 Aug 27;13(1):39 - PubMed
  125. Carcinogenesis. 2016 Sep;37(9):852-7 - PubMed
  126. J Cancer Epidemiol. 2009;2009:302047 - PubMed
  127. PLoS One. 2015 Jun 19;10(6):e0130388 - PubMed
  128. J Surg Res. 2010 Nov;164(1):e61-6 - PubMed
  129. Cancer. 2014 Nov 1;120(21):3329-3337 - PubMed

Publication Types